Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
Preferential Generation of Follicular B Helper T Cells from Foxp3 + T Cells in Gut Peyer's Patches
2009 StandoutScienceNobel
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
2003 StandoutScience
Epigenetic Silencing of Death Receptor 4 Mediates Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Resistance in Gliomas
2009
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130
2002 StandoutNobel
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Inadequate erythropoietin response to anemia: definition and clinical relevance
1994
De novo design of modular and tunable protein biosensors
2021 StandoutNatureNobel
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
1999
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
2007
The extracellular domain of Her2 in serum as a biomarker of breast cancer
2018
Herceptin: mechanisms of action and resistance
2005
The relationship between prognostic and predictive factors in the management of breast cancer
1998
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
2000
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 StandoutNature
Homozygous Inactivation of theNF1Gene in Bone Marrow Cells from Children with Neurofibromatosis Type 1 and Malignant Myeloid Disorders
1997
The effect of anemia treatment on selected health-related quality-of-life domains: A systematic review
2003
Base-excision repair of oxidative DNA damage
2007 StandoutNature
The therapeutic potential of interleukin-6 hyperagonists and antagonists
1997
Psychosocial interventions for patients with advanced cancer – a systematic review of the literature
2004
Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two–colour fluorescence analysis
1996
Analysis of the molecular mechanism involved in 2B4-mediated NK cell activation: evidence that human 2B4 is physically and functionally associated with the linker for activation of T cells
2000
Contribution ofBRCA1Mutations to Ovarian Cancer
1997
The DNA Damage Response Kinases DNA-dependent Protein Kinase (DNA-PK) and Ataxia Telangiectasia Mutated (ATM) Are Stimulated by Bulky Adduct-containing DNA
2011 StandoutNobel
Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors
2002
Interleukin-6 in Biology and Medicine
1993
On guard—activating NK cell receptors
2001
Trastuzumab: triumphs and tribulations
2007
New insights into nNOS regulation of vascular homeostasis
2005 StandoutNobel
Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2
1996
The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease
2003
Detection ofATMGene Mutation in Human Glioma Cell Line M059J by a Rapid Frameshift/Stop Codon Assay in Yeast
2002
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy
2011
Follicular B helper T cells in antibody responses and autoimmunity
2005
Cytokine Expression in Multiple Myeloma and Monoclonal Gammopathy: Analysis by Reverse Transcription/Polymerase Chain Reaction and Quantitative PCR
1996
The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM
1998 Nature
Mutations and Polymorphisms in the familial early-onset breast cancer (BRCA1) gene
1996
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%
1996
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer
1996
Targeting apoptosis in cancer therapy
2020 Standout
SLAM Family Receptors Distinguish Hematopoietic Stem and Progenitor Cells and Reveal Endothelial Niches for Stem Cells
2005 Standout
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
Risks of breast and testicular cancers in young adult twins in England and Wales: evidence on prenatal and genetic aetiology
1997
Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network
2008 Standout
Hereditary Colorectal Cancer
2003 Standout
Inflammation and cancer: back to Virchow?
2001 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
The Risk of Cancer Associated with Specific Mutations ofBRCA1andBRCA2among Ashkenazi Jews
1997 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Prevalence and outcomes of anemia in cancer: a systematic review of the literature
2004
Recombinant Human Single Chain Fv Antibodies Recognizing Human Interleukin-6
1998 StandoutNobel
Genomic analysis of circulating cell-free DNA infers breast cancer dormancy
2011
Jewish religion and risk of breast cancer
1996
Frequency and Carrier Risk Associated with Common BRCA1 and BRCA2 Mutations in Ashkenazi Jewish Breast Cancer Patients
1998
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
2006 Standout
BRCA1Mutations in a Population-Based Sample of Young Women with Breast Cancer
1996
The genetics of macrophage activation syndrome
2020
Mechanisms of Bone Metastasis
2004 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
2001 StandoutNature
The dual-function CD150 receptor subfamily: the viral attraction
2002
Environmental and Heritable Factors in the Causation of Cancer — Analyses of Cohorts of Twins from Sweden, Denmark, and Finland
2000 Standout
Interleukin‐6 and its receptor in cancer
2007
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
2009 Standout
The TRAIL apoptotic pathway in cancer onset, progression and therapy
2008
Epoetin alfa improves quality of life in patients with cancer
2004
Prostate cancer invasion and metastasis: insights from mining genomic data
2013
Anemia of Chronic Disease
2005 Standout
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer
1999
Epstein–Barr Virus Infection
2000 Standout
Anemia at the end of life: prevalence, significance, and causes in patients receiving palliative care
2003
Cancer of the Ovary
2004 Standout
Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers
2002
Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance
1999
Molecular and Functional Characterization of Mouse Signaling Lymphocytic Activation Molecule (SLAM): Differential Expression and Responsiveness in Th1 and Th2 Cells
1999
Cytokine Network in Human Multiple Myeloma
1992
Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers
2002
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
Selective Colorimetric Detection of Polynucleotides Based on the Distance-Dependent Optical Properties of Gold Nanoparticles
1997 StandoutScience
PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver
2003 StandoutNobel
X-Linked Lymphoproliferative Disease
2000
Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients
2006 StandoutNobel
Cutting Edge: Human 2B4, an Activating NK Cell Receptor, Recruits the Protein Tyrosine Phosphatase SHP-2 and the Adaptor Signaling Protein SAP
1999
CD150 Association with Either the SH2-Containing Inositol Phosphatase or the SH2-Containing Protein Tyrosine Phosphatase Is Regulated by the Adaptor Protein SH2D1A
2001
Treatment of E pstein B arr virus‐induced haemophagocytic lymphohistiocytosis with rituximab‐containing chemo‐immunotherapeutic regimens
2013
Circulating Tumor Cells in Breast Cancer: Detection Systems, Molecular Characterization, and Future Challenges
2012
Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
2001 Standout
Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells
1996
Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma
1995
Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells
2002 StandoutNobel
Oligosaccharyltransferase: A Gatekeeper of Health and Tumor Progression
2019
Cytokine Storm
2020 Standout
Prediction of response to erythropoietin treatment in chronic anemia of cancer [see comments]
1994
The soluble interleukin 6 receptor: mechanisms of production and implications in disease
2001
Circulating Tumor Cells in Breast Cancer:Detection Systems, Molecular Characterization, and Future Challenges
2011
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Alterations of the X-linked lymphoproliferative disease geneSH2D1A in common variable immunodeficiency syndrome
2001
Clinical and virologic characteristics of chronic active Epstein-Barr virus infection
2001
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components
2009 StandoutNobel
Molecular and functional characterization of mouse signaling lymphocytic activation molecule (SLAM): differential expression and responsiveness in Th1 and Th2 cells.
1999
Decoding the Patterns of Self and Nonself by the Innate Immune System
2002 StandoutScience
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Bioorthogonal Labeling of Human Prostate Cancer Tissue Slice Cultures for Glycoproteomics
2017 StandoutNobel
Regulatory roles of IL-10–producing human follicular T cells
2019 StandoutNobel
Human Cd4+ T Lymphocytes Consistently Respond to the Latent Epstein-Barr Virus Nuclear Antigen Ebna1
2000 StandoutNobel
Innate or Adaptive Immunity? The Example of Natural Killer Cells
2011 StandoutScience
Genetic Testing for Cancer Predisposition
2001
Cellular Responses to Viral Infection in Humans: Lessons from Epstein-Barr Virus
2007
Works of Michael Krainer being referenced
Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cellsin vitro
1997
Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer.
2004
Monitoring of Serum Her-2/ neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer
2004
Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients
2010
Tissue Expression and Serum Levels of HER-2/neu in Patients with Breast Cancer
1997
TUSC3 Loss Alters the ER Stress Response and Accelerates Prostate Cancer Growth in vivo
2014
Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs
2004
Decreased expression of ICAM-1 and its induction by tumor necrosis factor on breast-cancer cellsin vitro
1997
Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors
1993
Methylation status of TUSC3 is a prognostic factor in ovarian cancer
2012
Erythropoietin treatment of chronic anaemia of cancer
1993
Differential Contributions ofBRCA1andBRCA2to Early-Onset Breast Cancer
1997
Difference in patient's acceptance of early versus late initiation of psychosocial support in breast cancer
2001
Physical Map and Cosmid ContigEncompassing a New InterstitialDeletion of the X-LinkedLymphoproliférative Syndrome Region
1996
Increase of bone marrow cellularity during erythropoietin treatment in myeloma.
1995
Interleukin-6 is a prognostic factor in multiple myeloma [letter] [see comments]
1991
Perturbation of the Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Cascade in Ovarian Cancer: Overexpression of FLIPL and Deregulation of the Functional Receptors DR4 and DR5
2005
Interleukin-6 is a prognostic factor in multiple myeloma [letter] [see comments]
1991
Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome
1998
Tumor suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition and inhibits tumor growth by modulating the endoplasmic reticulum stress response in ovarian cancer cells
2015
Germ-LineBRCA1Mutations in Jewish and Non-Jewish Women with Early-Onset Breast Cancer
1996
Detection of heterozygous truncating mutations in the BRCA1 and APC genes by using a rapid screening assay in yeast
1997
Predictive value of interleukin-6 and neopterin in patients with multiple myeloma.
1991
Contribution of Epigenetic Silencing of Tumor Necrosis Factor–Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer
2005